Citations

Mayo Clinic

Showing 10 of 108523 citations.

Transcatheter Valve Therapy Registry Is A Model For Medical Device Innovation And Surveillance
Carroll, John D. , Shuren, Jeff, Jensen, Tamara Syrek, Hernandez, John , Holmes, David R. , Marinac‐Dabic, Danica , Edwards, Fred H., Zuckerman, Bram D., Wood, Larry, Kuntz, Richard E., Mack, Michael J. , Zuckerman, Bram

Health Affairs | February 2, 2015 | Volume: 34 | Issue: 2 | Pages: 328-334

10.1377/hlthaff.2014.1010 | PMID 25646114 Get It

Bioinformatics Strategies for Identifying Regions of Epigenetic Deregulation Associated with Aberrant Transcript Splicing and RNA-editing
Champion, Mia D., Hlady, Ryan A. , Yan, Huihuang , Evans, Jared M., Nie, Jeff, Nandakumar, Kannabiran, Davila, Jaime , Moore, Raymond M. , Nair, Asha, Zhu, Yuanxiao, Ördög, Tamás , Kocher, Jean-Pierre A., Jonasch, Eric, Tibes, Raoul , Lee, Jeong‐Heon , Bogenberger, James M. , O’Brien, Daniel J. , Kortüm, K. Martin , Zhang, Zhiguo , Joseph, Richard W. , Jonasch, Eric W. , Robertson, Keith D. , Ho, Thai H. , Davila, Jaime I

Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms | February 2, 2015 | Volume: No volume available | Issue: No issue available | Pages: 163-170

10.5220/0005248001630170 Get It

How to explain cystic adventitial disease coexisting in an adjacent artery and vein
Prasad, Nikhil , Desy, Nicholas M. , Amrami, Kimberly K. , Spinner, Robert J. , Prasad, Nikhil K.

Clinical Anatomy | February 2, 2015 | Volume: 28 | Issue: 7 | Pages: 833-835

10.1002/ca.22506 | PMID 25644633 Get It

Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing
Scherr, Courtney L. , Lindor, Noralane M. , Malo, Teri L. , Vadaparampil, Susan T. , Scherr, C L , Couch, Fergus J.

Clinical Genetics | February 2, 2015 | Volume: 88 | Issue: 6 | Pages: 523-529

10.1111/cge.12563 | PMID 25640009 Get It

Studies indicate variant of uncertain significance (VUS) results are challenging for genetic counselors and patients, often resulting in negative patient outcomes. Genetic counselors' current practices regarding VUS are unknown. This study utilized a national survey of genetic counselors (n = 932) to examine current practices and confidence related to disclosing BRCA VUS results and reclassification information. For participants (n = 398), descriptive statistics were calculated regarding patient demographic characteristics, practices and confidence, and cross tabulation was used to identify participant's actions when receiving a reclassified VUS. Upon receiving a BRCA VUS report, the majority reported providing patients with information about the frequency with which their VUS was seen and patient ancestry, but a minority discussed DNA banking. Most were confident in their understanding of, and ability to explain, VUS results to patients, but felt less confident about achieving high levels of patient understanding. Upon reclassification, the majority reported calling the patient and mailing the results, but when the reclassification was deleterious, the majority also met with the patient face‐to‐face. Given the lack of standard professional guidelines about informing patients of initial and reclassified VUS results, this overview provides important insight into genetic counselors' current practices and confidence.
Arthroscopic‐Assisted Reduction and Percutaneous Fixation of Tibial Plateau Fractures
Hartigan, David E. , McCarthy, Mark A., Krych, Aaron J. , Levy, Bruce A. , Krych, Aaron J

Arthroscopy Techniques | February 2, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.1016/j.eats.2014.11.002 | PMID 25973374 Get It

Abstract Tibial plateau fractures present a difficult range of fractures to treat. Arthroscopy allows for a less invasive option when compared with arthrotomy. Furthermore, visualization of the articular surface arthroscopically can allow for a precise reduction and assessment of any concomitant injuries to the articular cartilage and meniscus. By use of arthroscopy, unicondylar lateral plateaus were traditionally approached through a laterally based metaphyseal window. However, in carefully selected patients and fracture patterns, a medially based, arthroscopic‐assisted approach can create long bony tunnels for subchondral support and allow for greater ease in fracture reduction. We present our technique using a medial approach for arthroscopic‐assisted fixation of lateral tibial plateau fractures. Technique Video video See video under supplementary data.
Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells
Justilien, Verline , Fields, Alan P.

Clinical Cancer Research | February 2, 2015 | Volume: 21 | Issue: 3 | Pages: 505-513

10.1158/1078-0432.ccr-14-0507 | PMID 25646180 Get It

Abstract The Hedgehog (Hh) signaling pathway is critical for embryonic development. In adult tissues, Hh signaling is relatively quiescent with the exception of roles in tissue maintenance and repair. Aberrant activation of Hh signaling is implicated in multiple aspects of transformation, including the maintenance of the cancer stem cell (CSC) phenotype. Preclinical studies indicate that CSCs from many tumor types are sensitive to Hh pathway inhibition and that Hh-targeted therapeutics block many aspects of transformation attributed to CSCs, including drug resistance, relapse, and metastasis. However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types. This lack of success is likely due to many factors, including a lack of patient stratification in early trials, cross-talk between Hh and other oncogenic signaling pathways that can modulate therapeutic response, and a limited knowledge of Hh pathway activation mechanisms in CSCs from most tumor types. Here, we discuss Hh signaling mechanisms in the context of human cancer, particularly in the maintenance of the CSC phenotype, and consider new therapeutic strategies that hold the potential to expand considerably the scope and therapeutic efficacy of Hh-directed anticancer therapy. Clin Cancer Res; 21(3); 505–13. ©2015 AACR.
MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
Tomaszek, Sandra, Kosari, Farhad , Metintaş, Muzaffer , Jett, James R., Metintaş, Selma , Yıldırım, Hüseyin , Dündar, Emine , Dong, Jie , Aubry, Marie Christine, Wigle, Dennis A. , Thomas, Charles F., Tomaszek, Sandra C, Ak, Güntülü

BioMed Research International | February 1, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-8

10.1155/2015/635748 | PMID 25756049 Get It

Introduction. We investigated the expression of microRNAs and mRNAs in pleural tissues from patients with either malignant pleural mesothelioma or benign asbestos-related pleural effusion.Methods. Fresh frozen tissues from a total of 18 malignant pleural mesothelioma and 6 benign asbestos-related pleural effusion patients were studied. Expression profiling of mRNA and microRNA was performed using standard protocols.Results. We discovered significant upregulation of multiple microRNAs in malignant pleural mesothelioma compared to benign asbestos-related pleural effusion. Hsa-miR-484, hsa-miR-320, hsa-let-7a, and hsa-miR-125a-5p were able to discriminate malignant from benign disease. Dynamically regulated mRNAs were also identified. MET was the most highly overexpressed gene in malignant pleural mesothelioma compared to benign asbestos-related pleural effusion. Integrated analyses examining microRNA-mRNA interactions suggested multiple altered targets within the Notch signaling pathway.Conclusions. Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.
ACTH adenomas transforming their clinical expression: report of 5 cases
Zoli, Matteo , Faustini‐Fustini, Marco, Mazzatenta, Diego , Marucci, Gianluca , Carlo, Eugenio De, Bacci, A., Pasquini, Ernesto , Frank, Giorgio, Lanzino, Giuseppe , Zoli, Matteo

Neurosurgical Focus | February 1, 2015 | Volume: 38 | Issue: 2 | Pages: E15

10.3171/2014.11.focus14679 | PMID 25639317 Get It

OBJECT Adrenocorticotropic hormone (ACTH) adenomas have been recognized as a more aggressive and invasive subtype of pituitary adenomas. An additional and clinically relevant peculiarity of these tumors is their ability to modify their clinical expression from a silent form to Cushing disease or vice versa. The aim of this study was to review a series of patients with pituitary adenomas and analyze the clinical implications of the transformation of clinical expression in 5 cases that showed this phenomenon. METHODS The authors retrospectively reviewed a series of patients with pituitary adenoma and collected clinical, biohumoral, and neuroradiological data of those who presented with a transformation from silent ACTH adenomas to functioning tumors or vice versa. In all the cases, preoperative assessment consisted of brain MRI, ophthalmological examination, and complete baseline endocrinological investigation. In patients with clinical and/or biochemical findings suspicious for Cushing syndrome, a low-dose dexamethasone suppression test was performed to rule in or out this diagnosis. Endocrinological evaluations were repeated 1 month after surgery, 3 months after surgery, and every 6 months or annually thereafter. Ophthalmological evaluations and brain MRIs were repeated after 3 months and then every 6 or 12 months thereafter. RESULTS Five patients (2 men and 3 women) included in this series had corticotropic tumors that showed transformation from an endocrinologically silent form to manifest Cushing disease and vice versa. The mean age at presentation was 40 years (range 18–51 years). In 3 of these patients, a transformation from silent to functioning ACTH adenoma with manifest Cushing disease occurred. In 1 patient, the authors observed the transition from a functioning to a silent adenoma with spontaneous resolution of hypercortisolism. Another patient's silent adenoma “shifted” to a functioning adenoma and then regressed back to a silent form with spontaneous resolution of Cushing disease. This patient again developed hypercortisolism, which finally resolved spontaneously. In this series, the transformation occurred after a mean of 3.5 years (range 6 months to 7 years). The shift from an ACTH-silent to a functioning adenoma was observed in 9% of the ACTH-silent adenomas in this series (4 of 44 cases), and the spontaneous remission of Cushing disease to a silent corticotroph cell adenoma occurred in 1.5% of cases of this series (2 of 132 functioning ACTH adenomas). At follow-up (mean 107 months; range 60–177 months), cortisol levels were within normal limits in all 5 cases. However, 1 patient required Gamma Knife radiosurgery and eventually adrenalectomy for disease control to be achieved. CONCLUSIONS The ability of silent ACTH adenomas to transform their secretion pattern poses a challenge for neurosurgeons and endocrinologists. Because the transformation is often unexpected, the clinical and biochemical data can be underestimated. Furthermore, this bizarre and unpredictable postoperative tumor behavior can lead to misinterpretation of clinical and endocrinological outcomes. Even if these cases are very rare, they are not anecdotal in large series. Thus, ACTH adenomas require careful biohumoral and neuroradiological follow-up to detect possible transformations.
Segmental type 1 D arier disease: a case series highlighting late‐onset disease
Sartori‐Valinotti, Julio C. , Peters, Margot S. , Wieland, Carilyn N.

British Journal of Dermatology | February 1, 2015 | Volume: 173 | Issue: 2 | Pages: 587-589

10.1111/bjd.13704 | PMID 25639290 Get It

Psychological Therapies in Patients with Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Altayar, Osama , Sharma, Varun , Sood, Amit , Murad, M. Hassan , Murad, Mohammad Hassan, Prokop, Larry J. , Murad, M Hassan , Altayar, Osama

Gastroenterology Research and Practice | January 31, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-19

10.1155/2015/549308 | PMID 25802514 Get It

Background. Irritable bowel syndrome (IBS) is a poorly understood disease with few effective treatments. Psychosocial factors are believed to contribute to the pathogenesis of IBS.Objective. To evaluate the evidence for psychological therapies in IBS treatment.Methods. We searched six medical databases through February 6, 2014, for randomized controlled trials (RCTs) of psychological therapies for the treatment of IBS. Two independent reviewers identified the RCTs, extracted the data, and assessed trial quality. We used the random-effect model to pool standardized mean difference (SMD) and 95% confidence interval (CI) across trials.Results. 15 RCTs that mostly evaluated cognitive behavioral therapy were included. Psychological therapies were associated with improvement in IBS symptoms severity scales (SMD −0.618; 95% CI: −0.853 to −0.383), IBS-Quality of Life (SMD 0.604; 95% CI: 0.440 to 0.768), and abdominal pain (SMD −0.282; 95% CI: −0.562 to −0.001). No statistically significant effect was observed on diarrhea or constipation.Limitations. The trials were at increased risk of bias and the overall sample size was small leading to imprecision.Conclusion. Psychological therapies may improve the quality of life and symptom severity in IBS. The effect size noted is moderate to large and is clinically meaningful.